Lake Street lowered the firm's price target on Artivion to $45 from $55 and keeps a Buy rating on the shares. The guidance pulldown on lower-than-anticipated Stent growth was "disappointing," but the firm believes challenges are "transient and manageable," the analyst tells investors.
